ACHIEVE LIFE SCIENCES, INC. — Investor Relations & Filings

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company dedicated to addressing the global nicotine dependence epidemic. The company's primary focus is the development and commercialization of its lead product candidate, cytisinicline, for smoking cessation. Following the successful completion of two Phase 3 studies, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), which has been accepted for review. If approved, cytisinicline has the potential to become the first new FDA-approved treatment option for nicotine dependence in the United States in nearly two decades.